天际股份募投项目二次延期 业绩仍陷亏损大股东减持

Core Viewpoint - Tianji Co., Ltd. announced a delay in the completion of its fundraising project for "30,000 tons of lithium hexafluorophosphate and 6,000 tons of high-purity lithium fluoride" to December 2026, which was previously postponed from December 2024 to December 2025 [1] Financial Performance - For the first three quarters of 2025, the company reported revenue of 1.786 billion yuan, a year-on-year increase of 23.00%, but still incurred a net loss of 101 million yuan [1] - The net cash flow from operating activities was -368 million yuan, with cash received from sales and services amounting to 1.407 billion yuan [1] Debt and Liquidity - As of the third quarter of 2025, the company's interest-bearing debt reached 1.158 billion yuan, a year-on-year increase of 31.26% [2] - Cash and cash equivalents decreased from 977 million yuan in the previous year to 593 million yuan, a decline of 39.35% [2] - The ratio of cash to current liabilities was only 38.17%, and the average operating cash flow to current liabilities ratio over the past three years was 16.91% [2] Project Funding and Use of Proceeds - The fundraising project is expected to require approximately 876 million yuan, with a cumulative investment of 698 million yuan as of November 30, 2025, representing an investment progress of 79.66% [1] - Of the unused fundraising amount (including interest), 175 million yuan has been temporarily used to supplement working capital, leaving approximately 11.12 million yuan in the dedicated fundraising account [1] Shareholder Activity - In September 2025, the controlling shareholder reduced its stake by selling 3 million shares, decreasing its ownership from 18.26% to 17.65% [3] - The reduction was part of a previously disclosed plan allowing for a maximum reduction of 3% of the total share capital within three months after the announcement [3] Market and Operational Challenges - The company cited "customer demand, market environment, and development planning" as reasons for the project delay, while asserting that there are no significant adverse conditions affecting the normal progress of the fundraising plan [3] - The gross margin for the main product, lithium hexafluorophosphate, was reported at -0.5%, indicating a loss [3]